Spero Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $66.8M | $48.0M | $103.8M | $53.5M | $18.3M |
| Operating income | $6.3M | -$73.4M | $21.5M | -$42.2M | -$88.0M |
| Operating expenses | $60.5M | $121.3M | $82.3M | $95.7M | $106.2M |
| Cash from operations | -$12.6M | -$23.4M | -$33.0M | -$7.7M | -$64.3M |
| Impairments | $587,000 | $0 | $5.3M | $635,000 | $0 |
| Total assets | $68.9M | $110.5M | $182.4M | $124.8M | $171.1M |
| Total liabilities | $9.9M | $64.4M | $75.5M | $48.9M | $82.8M |
Shares outstanding 57.9M · Free float 78.0%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.